Welcome to our dedicated page for Enlivex Therapeutics news (Ticker: ENLV), a resource for investors and traders seeking the latest updates and insights on Enlivex Therapeutics stock.
Enlivex Therapeutics Ltd (ENLV) is a clinical-stage biopharmaceutical company pioneering macrophage-reprogramming therapies through its lead candidate Allocetra. This page provides investors and researchers with timely updates on clinical trials, regulatory milestones, and strategic developments across its pipeline targeting immune dysregulation.
Access primary-source ENLV news including clinical trial results, research collaborations, and regulatory filings related to Allocetra's development in sepsis, osteoarthritis, and autoimmune conditions. Our curated news collection enables efficient tracking of the company's progress in creating off-the-shelf cell therapies designed to restore immune homeostasis.
Key updates include advancements in Phase I/II trials, manufacturing partnerships, and peer-reviewed data publications. Bookmark this page for direct access to ENLV's official press releases and objective third-party analysis of their innovative approach to immune rebalancing therapies.
Enlivex Therapeutics (Nasdaq: ENLV) announced its participation at the Osteoarthritis Research Society International (OARSI) 2025 World Congress in Incheon, South Korea, scheduled for April 24-27, 2025. The company will present two poster abstracts showcasing their cell therapy product Allocetra™.
The presentations will highlight data from both preclinical and Phase I/II clinical studies of Allocetra™, their proprietary off-the-shelf macrophage reprogramming cell therapy. The therapy has shown promising results in moderate and end-stage osteoarthritis, demonstrating favorable safety profiles, significant pain reduction, improved joint function, and helped patients avoid knee replacement surgery.
Two presentations are scheduled: a Flash Talk & Poster presentation on Phase I/II Clinical Trial results (Abstract #092) and a Poster presentation on Allocetra's biological activity in preclinical models (Abstract #4231304). CEO Dr. Oren Hershkovitz and CMO Dr. Einat Galamidi will be available for meetings during the conference.
Enlivex Therapeutics (Nasdaq: ENLV) has completed patient enrollment in the Phase II stage of its Phase I/II clinical trial evaluating Allocetra™ for moderate to severe knee osteoarthritis treatment. The randomized, controlled, and blinded study successfully enrolled 133 patients. Following promising initial efficacy data from the Phase I stage, the company expects to receive 3-month topline data by August 2025.
Enlivex Therapeutics (Nasdaq: ENLV) has initiated dosing in a Phase I trial evaluating Allocetra™ for temporomandibular joint (TMJ) osteoarthritis patients. The investigator-initiated study, conducted at Sheba Medical Center, aims to assess the safety, tolerability, and initial efficacy of Allocetra™ when injected into the TMJ.
The trial will enroll six patients who have not responded adequately to conventional TMJ osteoarthritis treatments. The study's primary safety endpoint will evaluate adverse events frequency and severity, while efficacy endpoints will measure changes in TMJ pain, joint functionality, and other disease parameters over a 12-month follow-up period.
TMJ osteoarthritis, affecting 5-12% of the global population, is a degenerative and progressive condition causing jaw pain and stiffness, with currently no effective long-term treatments available.
Enlivex Therapeutics (Nasdaq: ENLV) has received a notice of allowance from China's CNIPA for patent application 2020800620493, covering the use of Allocetra™ in treating osteoarthritis patients. The patent, expected to be issued in H1 2025, will provide protection through 2040.
The company recently reported positive interim 6-month efficacy data from its Phase I/II Allocetra™ trial in moderate to severe knee osteoarthritis patients. Key results include:
- 47.0% average reduction in reported pain (P=0.0001) vs baseline
- 46% improvement in joint function
- 40% improvement in joint stiffness
- 83% of patients remained treatment responders after 6 months
- No serious adverse events reported
- Maintained positive effects observed at 3 months
Enlivex Therapeutics (NASDAQ: ENLV) has announced a webinar to discuss positive interim data from its Phase I/II Allocetra™ trial in knee osteoarthritis patients. The six-month data from the Phase I stage showed significant improvements with:
- 47.0% average reduction in reported pain (P=0.0001)
- 46% improvement in joint function
- 83% of patients maintaining response at six months post-treatment
The results demonstrate Allocetra™'s potential as a breakthrough treatment for moderate to severe knee osteoarthritis, with no serious adverse events reported. The investor webinar is scheduled for March 5, 2025, at 11:00 a.m. ET, featuring CEO Oren Hershkovitz Ph.D., who will provide detailed insights into these promising interim results.
Enlivex Therapeutics (NASDAQ: ENLV) has reported positive interim six-month efficacy data from its Phase I/II Allocetra™ trial for moderate to severe knee osteoarthritis treatment. The data showed a statistically significant 47.0% reduction in pain (P=0.0001) compared to baseline, with 83% of patients responding to treatment after 6 months.
Key improvements include a 46% enhancement in joint function and 40% improvement in joint stiffness. The trial demonstrated strong persistence and durability, maintaining the positive effects observed at 3 months. No serious adverse events were reported, with only mild transient discomfort/pain or swelling following injections.
The trial is currently progressing to its Phase II stage, a double-blind, randomized, placebo-controlled study. The company expects topline data readout by Q3 2025, evaluating joint-pain and function compared to placebo at three, six, and 12 months post-treatment.
Enlivex Therapeutics (ENLV) has issued an urgent statement addressing false information published by Tipranks.com claiming the company had suspended stock trading due to an internal investigation. The company strongly denies these claims, confirming that its shares continue to trade normally on both the Tel Aviv Stock Exchange and NASDAQ without interruption.
CEO Oren Hershkovitz characterized the incident as a deliberate attempt to manipulate public perception and mislead investors. The company plans to pursue legal action against those responsible, including the publishers and the hosting service of Tipranks.com. Enlivex maintains that it continues to execute its operating plan, focusing on developing AllocetraTM for osteoarthritis treatment.
Enlivex Therapeutics (NASDAQ:ENLV) will be featured on Bloomberg TV's RedChip Small Stocks, Big Money™ show on January 11, 2025, at 7 p.m. ET. CEO Oren Hershkovitz will provide a corporate update focusing on their Allocetra™ platform, a universal, off-the-shelf cell therapy designed to reprogram macrophages.
The company has achieved significant progress with promising Phase I/II clinical trial results in multiple indications, including knee osteoarthritis and psoriatic arthritis. In 2024, Enlivex initiated a multi-country, randomized trial evaluating Allocetra™ in up to 160 patients with moderate to severe knee osteoarthritis, with key data expected by Q3 2025.
Enlivex Therapeutics (Nasdaq: ENLV) has received authorization from the Israeli Ministry of Health to begin a Phase I trial evaluating Allocetra™ in patients with temporomandibular joint (TMJ) osteoarthritis. The investigator-initiated trial will be conducted at Sheba Medical Center, recently ranked among the world's top 10 hospitals by Newsweek.
The study aims to recruit six patients who haven't responded adequately to conventional TMJ osteoarthritis treatments. The trial will assess safety through monitoring adverse events, while efficacy endpoints will evaluate changes in TMJ pain, joint functionality, and other disease parameters for up to 12 months post-treatment.
Enlivex Therapeutics announced positive interim efficacy data from its Phase I/II Allocetra™ trial for moderate to severe knee osteoarthritis. The Phase I stage showed statistically significant results (p-value < 0.0007, n=12) with marked improvements in key efficacy endpoints. The treatment demonstrated a 50% reduction in average knee joint pain, 42% improvement in knee joint function, and 37% reduction in knee joint stiffness after three months. Among participants, 83% were responders to Allocetra™, showing >40% pain reduction from baseline. The trial is now enrolling patients for the Phase II stage, which is double-blind, randomized, and placebo-controlled.
